respiratori
syncyti
viru
rsv
lead
caus
acut
lower
respiratori
tract
infect
infant
young
children
licens
rsv
vaccin
avail
treatment
option
highrisk
individu
either
extrem
costli
caus
sever
side
effect
toxic
immunomodul
mediat
novel
formul
consist
tolllik
receptor
agonist
poli
c
innat
defens
regul
peptid
polyphosphazen
pip
evalu
context
lethal
infect
pneumonia
viru
mice
pvm
intranas
deliveri
singl
dose
pip
protect
adult
mice
pvm
given
h
prior
challeng
anim
experienc
minim
weight
loss
clinic
diseas
surviv
reduc
lung
patholog
similar
clinic
outcom
observ
mice
treat
day
prior
infect
pip
pretreat
induc
earli
mrna
protein
express
key
chemokin
cytokin
gene
reduc
recruit
neutrophil
eosinophil
decreas
viru
titer
lung
modul
delay
exacerb
natur
pvm
diseas
without
shortterm
side
effect
day
postinfect
piptreat
mice
confirm
pvmfree
result
demonstr
capac
formul
prevent
pvm
possibl
viral
respiratori
infect
rsv
common
caus
bronchiol
pneumonia
infant
young
children
garg
et
al
graham
anderson
licens
rsv
vaccin
recommend
treatment
rsv
bronchiol
respiratori
support
hydrat
patient
shaw
et
al
palivizumab
use
prophylact
exclus
highrisk
infant
unfortun
use
limit
patient
develop
countri
due
extrem
high
cost
logist
inject
graham
anderson
shaw
et
al
hurwitz
ribavirin
also
util
treatment
rsv
infect
highrisk
young
children
effici
induc
sever
advers
effect
graham
anderson
rosenberg
et
al
better
anim
model
studi
rsv
pathogenesi
aris
use
pneumovirus
match
associ
host
provid
accur
represent
natur
infect
diseas
graham
anderson
pneumonia
viru
mice
pvm
consid
potenti
model
rsv
infect
watkiss
et
al
pvm
close
relat
rsv
belong
viral
famili
subfamili
induc
similar
disord
natur
host
easton
et
al
bem
et
al
make
suitabl
model
studi
rsvinduc
inflamm
contribut
sever
respiratori
diseas
outcom
demonstr
novel
adjuv
platform
combin
rsv
fusion
protein
induc
longlast
immun
respons
rsv
sever
anim
model
garg
et
al
garg
et
al
garg
et
al
first
compon
formul
poli
c
promot
immun
respons
induc
high
level
type
ifn
zhao
et
al
tewari
et
al
second
compon
innat
defens
regul
idr
peptid
deriv
bovin
bactenecin
possess
immunomodulatori
properti
nijnik
et
al
wu
hancock
hilchi
et
al
lastli
adjuv
platform
contain
poli
di
sodiumcarboxylatoethylphenoxi
phosphazen
pcep
synthet
watersolubl
polym
act
deliveri
system
modul
innat
immun
respons
mutwiri
et
al
awat
et
al
combin
poli
c
idr
peptid
pcep
pip
gener
immunomodul
potenti
altern
strategi
prevent
infecti
diseas
current
studi
assess
potenti
pip
protect
balbc
mice
lethal
infect
base
clinic
diseas
viral
replic
also
examin
natur
inflammatori
respons
induc
pip
treatment
delin
possibl
mechan
action
formul
propag
babi
hamster
kidney
atcc
manassa
va
usa
cell
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
st
loui
mo
usa
contain
fetal
bovin
serum
mm
nonessenti
amino
acid
mm
hepe
mgml
gentamicin
thermo
fisher
scientif
waltham
usa
watkiss
et
al
shrivastava
et
al
five
six
weekold
femal
balbc
mice
charl
river
laboratori
saintconst
qc
canada
given
ml
phosphatebuff
salin
pb
thermo
fisher
scientif
pip
intranas
lung
collect
select
time
point
evalu
abil
pip
elicit
protect
viral
infect
mice
given
intranas
treatment
pb
pip
challeng
day
later
pfu
ml
pip
formul
contain
mg
poli
c
invivogen
san
diego
ca
usa
mg
idr
peptid
genscript
piscataway
nj
usa
mg
pcep
idaho
nation
laboratori
idaho
fall
id
usa
pb
ratio
pip
formul
optim
use
adjuv
kovacsnolan
et
al
full
descript
treatment
group
experi
provid
tabl
five
mice
per
group
score
weigh
daili
accord
modifi
version
morton
griffith
guidelin
morton
griffith
day
postinfect
pi
remain
mice
euthan
case
lung
surviv
mice
collect
analysi
anim
trial
conduct
accord
canadian
council
anim
care
h
posttreat
pt
day
pi
singlelob
lung
collect
trizol
reagent
thermo
fisher
scientif
gene
express
studi
multilob
lung
collect
viru
titrat
multiplex
elisa
lung
homogen
use
mini
beadbeat
biospec
product
inc
bartlesvil
ok
usa
centrifug
c
remov
gross
debri
immedi
sampl
aliquot
flashfrozen
liquid
nitrogen
store
c
pvm
titrat
perform
describ
previous
watkiss
et
al
shrivastava
et
al
absolut
pvm
copi
number
calcul
via
quantit
realtim
pcr
qpcr
use
serial
dilut
standard
curv
stock
pvm
rna
nanogram
primer
specif
small
hydrophob
sh
gene
viru
unknown
rna
concentr
calcul
follow
equat
curv
copi
number
determin
accord
avogadro
number
sh
gene
amplicon
size
total
rna
extract
singlelob
lung
trizol
reagent
thermo
fisher
scientif
complementari
dna
cdna
synthesi
perform
use
quantitect
revers
transcript
kit
qiagen
venlo
limburg
netherland
qpcr
carri
use
faststart
sybr
green
master
roch
basel
switzerland
primer
thermo
fisher
scientif
anneal
temperatur
use
experi
list
tabl
result
normal
averag
bactin
level
pb
pb
medium
control
anim
multilob
lung
homogen
dmem
aliquot
proteas
inhibitor
solut
sigmaaldrich
flashfrozen
day
pi
msd
multispot
vplex
assay
proinflammatori
panel
tnfa
il
fig
protein
express
level
chemokin
cytokin
gene
lung
homogen
h
pt
mice
given
intranas
treatment
pb
pip
multilob
lung
mice
per
group
collect
separ
individu
anim
time
point
indic
protein
express
assay
electrochemiluminescencebas
multiplex
elisa
panel
h
repres
protein
express
data
pgml
tnfa
total
ifng
respect
data
shown
individu
valu
repres
singl
anim
well
median
interquartil
rang
five
biolog
replic
p
p
msd
multiarray
mous
cytokin
ultrasensit
assay
use
quantifi
cytokin
type
ii
ifn
chemokin
level
lung
meso
scale
discoveri
rockvil
md
usa
lung
singlecel
suspens
gener
previous
describ
watkiss
et
al
shrivastava
et
al
identifi
differ
leukocyt
popul
cell
block
truestain
fcx
biolegend
san
diego
ca
usa
stain
correspond
fluorochromeconjug
antibodi
cocktail
tabl
flow
cytometri
perform
use
fac
calibur
bd
bioscienc
franklin
lake
nj
usa
analysi
flow
cytometri
data
perform
use
kaluza
softwar
beckman
coulter
inc
pasadena
ca
usa
multilob
lung
perfus
neutral
buffer
formalin
nbf
vwr
radnor
pa
usa
collect
day
pt
day
pi
perfus
lung
embed
paraffin
section
duplic
mm
section
stain
hematoxylin
eosin
h
e
score
blind
manner
veterinari
pathologist
score
given
base
presenc
sever
distribut
lesion
lung
lobe
score
denot
normal
lung
score
repres
sign
mild
moder
sever
perivascular
edema
perivascul
cellular
infiltr
within
pulmonari
parenchyma
respect
graphpad
prism
use
analyz
data
graphpad
softwar
inc
la
jolla
ca
usa
differ
among
group
assess
use
student
ttest
oneway
anova
newmankeul
method
multipl
comparison
differ
consid
signific
p
mice
treat
intranas
pip
h
pt
gene
protein
express
profil
select
cytokin
chemokin
monitor
highest
gene
express
detect
h
pt
highest
mrna
product
detect
h
pt
fig
fig
effect
pip
treatment
cellular
recruit
immun
cell
histolog
lung
tissu
mice
given
intranas
treatment
pb
pip
lung
mice
per
group
collect
pool
process
time
point
indic
total
number
alveolar
macrophag
dc
b
neutrophil
c
eosinophil
nk
cell
e
lung
analyz
flow
cytometri
result
present
cell
number
x
per
million
cell
histolog
experi
five
mice
per
group
treat
previous
describ
h
pt
multilob
lung
collect
panel
f
g
repres
lung
histolog
section
magnif
respect
pip
group
data
shown
median
interquartil
rang
three
technic
replic
per
cell
type
assay
p
p
p
p
similarli
highest
protein
express
detect
within
first
h
follow
pip
treatment
fig
b
howev
time
point
protein
concentr
decreas
respect
furthermor
pip
treatment
induc
moder
upregul
tnfa
mrna
h
pt
level
decreas
later
time
point
fig
highest
protein
concentr
tnfa
detect
h
pt
fig
h
amount
significantli
decreas
respect
h
pt
level
cytokin
decreas
protein
concentr
pgml
h
pt
next
two
time
point
quantiti
significantli
reduc
respect
fig
interestingli
mrna
moder
upregul
within
first
h
pt
increas
approxim
h
pt
fig
similarli
protein
concentr
highest
timepoint
fig
delay
express
attribut
uniqu
role
dampen
immun
respons
vivo
highest
level
ifna
mrna
express
detect
h
pt
maxim
ifnb
mrna
express
occur
h
pt
ifng
mrna
also
reach
peak
h
pt
h
pt
mrna
level
strongli
declin
fig
similarli
ifng
protein
product
highest
h
pt
follow
signific
continu
decreas
thereaft
fig
number
alveolar
macrophag
dendrit
cell
dc
neutrophil
eosinophil
natur
killer
nk
cell
tissu
quantifi
alveolar
macrophag
eosinophil
number
low
peak
h
pt
fig
dc
nk
cell
count
increas
h
pt
remain
steadi
day
follow
pip
treatment
fig
e
neutrophil
number
peak
h
pt
declin
significantli
overtim
fig
consid
neutrophil
number
lung
higher
h
pt
histolog
studi
perform
determin
event
lead
lesion
toxic
vivo
h
pt
mild
form
lymphocyt
perivascul
peribronchiol
observ
fig
g
lesion
lifethreaten
suggest
increas
cellular
recruit
conclud
p
fig
outlin
trial
weight
chang
clinic
surviv
score
pipor
pbstreat
balbc
mice
intranas
pvm
challeng
mice
given
intranas
treatment
pip
pb
h
prior
challeng
pfu
anim
weigh
score
treatment
ie
day
day
challeng
ie
day
day
infect
panel
highlight
event
occur
anim
trial
collect
lung
tissu
viru
titrat
cell
influx
mrnaprotein
express
studi
schedul
day
prior
infect
pi
lung
sampl
histopatholog
studi
collect
day
pi
day
pi
qpcr
perform
survivor
mice
determin
pvm
statu
panel
b
illustr
weight
loss
mice
follow
pip
treatment
pvm
infect
median
percentag
start
weight
error
bar
indic
interquartil
rang
star
indic
differ
pippvm
pbspvm
group
panel
c
repres
surviv
rate
median
percentag
total
number
anim
per
group
day
follow
infect
panel
e
show
clinic
score
weight
loss
appear
repres
median
valu
group
throughout
entir
anim
trial
experi
perform
twice
averag
n
total
number
anim
equal
per
group
p
ip
induc
control
inflammatori
respons
impact
appear
behaviour
bodi
weight
anim
subsequ
examin
whether
pip
pretreat
might
protect
balbc
mice
lethal
pvm
challeng
deliv
treatment
h
prior
viru
inocul
chemokin
cytokin
mrna
protein
level
high
yet
display
balanc
profil
detect
h
pt
piptreat
anim
exhibit
minim
weight
loss
fig
overt
sign
clinic
diseas
fig
e
surviv
day
pi
fig
piptreat
mice
significantli
lower
number
viabl
virion
viral
mrna
copi
lung
compar
pbstreat
group
fig
b
day
pi
lung
homogen
survivor
mice
pcrneg
mrna
suggest
pip
pretreat
promot
complet
clearanc
viru
vivo
data
shown
lung
patholog
induc
pvm
infect
pipand
pbstreat
mice
examin
subsequ
trial
lung
pippvm
group
show
peribronchiol
perivascul
lymphocyt
multifoc
subacut
chronic
indic
mild
reaction
chronic
indic
function
problem
fig
contrast
pbspvm
group
sign
perivascular
edema
perivascul
limit
cellular
infiltr
within
pulmonari
parenchyma
acut
sever
reaction
indic
pulmonari
damag
function
problem
fig
note
larg
portion
infiltr
cell
polymorphonuclear
leukocyt
pmn
mostli
form
neutrophil
granulocyt
fig
g
statist
signific
differ
lung
patholog
piptreat
pbstreat
pvminfect
mice
suggest
treatment
pip
reduc
number
sever
lesion
lung
follow
otherwis
lethal
pvm
infect
fig
natur
immun
respons
induc
pip
lethal
pvm
infect
also
examin
gene
protein
level
piptreat
mice
show
earli
upregul
mrna
day
pi
compar
pbstreat
anim
confirm
protein
level
next
two
time
point
follow
pvm
infect
chemokin
express
remain
fairli
stabl
chang
time
fig
b
contrast
pbstreat
mice
express
increas
amount
two
chemokin
molecul
time
fig
b
piptreat
anim
display
slightli
upregul
mrna
level
tnfa
day
pi
fig
similarli
higher
cytokin
protein
concentr
detect
mice
day
pi
compar
pbstreat
mice
fig
except
increas
time
piptreat
group
continu
rel
stabl
cytokin
gene
protein
express
profil
throughout
remain
day
follow
pvm
infect
convers
cytokin
gene
protein
express
profil
pbstreat
group
character
increas
level
molecul
time
highest
overal
express
detect
day
pi
overal
piptreat
mice
display
lower
cytokin
protein
concentr
day
pi
compar
pbstreat
anim
piptreat
anim
display
earlier
express
type
ifn
mrna
compar
pbstreat
mice
fig
day
pi
mice
experienc
signific
drop
ifna
ifnb
mrna
level
contrast
pbstreat
anim
show
slightli
delay
express
type
ifn
highest
ifna
ifnb
mrna
express
day
pi
respect
piptreat
mice
display
elev
level
ifng
mrna
protein
day
pi
significantli
higher
detect
pbstreat
anim
fig
contrast
pbstreat
mice
ifng
mrna
protein
express
highest
day
pi
view
signific
infiltr
pmn
lung
pbstreat
pvminfect
mice
influx
differ
innat
immun
cell
lung
measur
piptreat
mice
show
increas
number
alveolar
macrophag
day
pi
fig
pvm
titer
absolut
viru
copi
number
lung
pip
pretreat
balbc
mice
day
prior
infect
pi
multilob
lung
homogen
dmem
use
viru
titrat
panel
show
log
pvm
titer
lung
tissu
express
pfug
singlelob
lung
process
trizol
use
qpcr
panel
b
show
log
absolut
pvm
mrna
copi
number
determin
describ
materi
method
section
data
repres
median
interquartil
rang
five
biolog
replic
per
group
experi
repeat
twice
p
p
peak
day
pi
fig
furthermor
pip
treatment
mediat
earli
dc
influx
lung
mice
number
significantli
higher
pbstreat
pvminfect
anim
fig
piptreat
anim
neutrophil
infiltr
character
earli
transient
recruit
lung
prior
pvm
infect
pvm
challeng
number
tend
decreas
level
contrast
pbstreat
pvminfect
mice
start
low
neutrophil
count
infect
progress
valu
drastic
increas
time
fig
day
pi
pbstreat
pvminfect
mice
greatli
elev
level
neutrophil
lung
suggest
neutrophilia
eosinophil
number
pbstreat
pvminfect
mice
went
day
pi
continu
increas
thereaft
howev
piptreat
anim
display
littl
eosinophil
recruit
similar
pbsmedium
group
fig
lastli
pip
treatment
induc
recruit
nk
cell
lung
day
pi
day
pi
nk
cell
influx
decreas
reach
number
compar
pbsmedium
group
interestingli
pbstreat
pvmchalleng
mice
delay
nk
cell
recruit
highest
number
day
pi
fig
investig
durat
protect
pip
capabl
confer
mice
lethal
infect
pvm
anim
fig
lung
patholog
balbc
mice
pretreat
pip
pb
h
prior
intranas
pvm
challeng
four
five
mice
per
group
treat
previous
describ
infect
intranas
pfu
pvm
lung
sampl
collect
day
pi
panel
b
repres
lung
section
magnif
respect
pbsmedium
control
group
panel
c
show
lung
section
magnif
respect
mice
treat
pip
panel
e
g
illustr
lung
section
pbstreat
mice
magnif
respect
white
arrow
point
sever
area
edema
tissu
well
pmn
within
region
panel
h
show
lung
histopatholog
score
given
basi
sever
dissemin
lesion
visibl
duplic
lung
section
data
repres
individu
median
valu
group
error
bar
indic
interquartil
rang
p
treat
day
prior
infect
experienc
less
weight
loss
surviv
fig
b
mice
low
clinic
score
appear
fig
mice
treat
day
prior
challeng
gradual
increas
weight
loss
clinic
score
lower
surviv
rate
fig
regardless
day
treatment
survivor
mice
day
trial
pvmneg
day
pi
experi
show
pip
still
good
activ
day
prior
infect
present
studi
assess
potenti
novel
immunomodulatori
compound
pip
pvm
diseas
model
altern
approach
prevent
sever
respiratori
infect
pip
significantli
upregul
express
gene
involv
host
defens
within
first
h
pt
thereaft
level
decreas
expect
due
rel
short
halfliv
pip
prophylaxi
h
prior
pvm
challeng
prevent
weight
loss
clinic
symptom
reduc
lung
immunopatholog
confer
complet
surviv
addit
pip
found
superior
formul
compar
poli
c
idr
peptid
pcep
alon
data
shown
pip
caus
observ
advers
effect
evidenc
absenc
clinic
sign
follow
treatment
interestingli
pip
mediat
substanti
reduct
neutrophil
eosinophil
influx
pvm
infect
induc
earli
recruit
nk
cell
dc
lung
lastli
protect
effect
pip
maintain
deliv
earli
day
prior
lethal
challeng
survivor
mice
deem
pvmfree
day
pi
suggest
pip
modul
host
immun
respons
trigger
complet
clearanc
viru
site
infect
immunomodulatori
regim
two
major
goal
enhanc
pathogen
clearanc
suppress
undesir
immun
respons
regard
pvm
well
rsv
effect
therapeut
approach
antivir
immunomodulatori
natur
rosenberg
et
al
bonvil
et
al
one
group
demonstr
principl
pvm
inject
mice
ribavirin
togeth
blockad
either
genedelet
antibodi
bonvil
et
al
order
achiev
desir
outcom
two
daili
dose
ribavirin
singl
daili
dose
antibodi
requir
period
day
bonvil
et
al
mention
previous
ribavirin
known
induc
toxic
sever
side
effect
pediatr
patient
discourag
use
popul
advantag
pip
treatment
includ
fact
indirectli
induc
moder
antivir
activ
downmodul
level
chemokin
cytokin
tnfa
pvm
infect
context
respiratori
viral
infect
alveolar
macrophag
key
mediat
viral
clearanc
diseas
resolut
vivo
tumpey
et
al
kolli
et
al
one
group
recent
show
deplet
alveolar
macrophag
prior
rsv
infect
result
increas
viru
titer
lung
exacerb
diseas
lung
inflamm
kolli
et
al
pip
treatment
associ
enhanc
viral
clearanc
reduc
immunopatholog
higher
alveolar
macrophag
number
lung
lethal
pvm
infect
like
latter
event
provid
piptreat
mice
advantag
alveolar
macrophag
known
dampen
excess
inflammatori
respons
within
lung
microenviron
pribul
et
al
suggest
neutrophil
may
play
import
role
regul
local
immun
gabelloni
et
al
one
studi
show
uncontrol
influx
neutrophil
activ
influenza
infect
lead
sever
lung
inflamm
tate
fig
heat
map
chemokin
cytokin
mrna
express
profil
pipor
pbstreat
balbc
mice
intranas
pvm
challeng
mice
given
intranas
treatment
pb
pip
h
challeng
pfu
pvm
singlelob
lung
mice
per
group
collect
day
prior
infect
pi
ct
valu
normal
bactin
level
control
anim
normal
foldchang
calcul
perform
use
method
data
shown
median
five
biolog
replic
fig
protein
express
level
chemokin
cytokin
gene
pip
pretreat
pvminfect
balbc
mice
mice
given
intranas
treatment
pb
pip
h
challeng
pfu
pvm
multilob
lung
mice
per
group
collect
separ
individu
anim
day
prior
infect
pi
protein
express
assay
electrochemiluminescencebas
multiplex
elisa
panel
h
repres
protein
express
data
pgml
tnfa
total
ifng
respect
data
shown
individu
valu
repres
singl
anim
well
median
interquartil
rang
five
biolog
replic
p
p
drescher
bai
similarli
promin
granulocyt
accumul
lung
hallmark
pvm
infect
eventu
progress
pulmonari
edema
respiratori
distress
bonvil
et
al
contrast
one
group
show
mice
deplet
neutrophil
establish
influenza
infect
result
increas
morbid
mortal
tumpey
et
al
drescher
bai
evid
suggest
neutrophil
infiltr
properli
control
benefici
reduc
diseas
ie
promot
viral
clearanc
interestingli
earli
neutrophil
influx
detect
piptreat
mice
possibl
treatment
mediat
moder
neutrophil
recruit
lung
product
chemoattract
like
mice
show
sign
neutrophilia
other
show
nk
cell
recruit
take
place
later
time
point
pvm
infect
watkiss
et
al
van
helden
et
al
correl
increas
lung
viru
titer
suggest
nk
cell
recruit
occur
late
benefici
treatment
pip
direct
effect
nk
cell
infiltr
formul
mediat
express
nk
cell
chemoattract
lung
ie
within
tissu
cell
like
find
optim
environ
support
activ
autocrin
product
ifng
vivier
et
al
consequ
ifng
act
directli
alveolar
macrophag
lead
activ
increas
phagocyt
activ
schroder
et
al
advantag
pip
mice
earli
local
antivir
immun
respons
prior
pvm
exposur
fig
infiltr
immun
cell
popul
lung
pip
pretreat
balbc
mice
day
prior
infect
follow
lethal
pvm
challeng
mice
given
intranas
treatment
pb
pip
h
prior
challeng
pfu
pvm
lung
mice
per
group
collect
pool
process
time
point
indic
follow
physic
chemic
digest
tissu
singlecel
suspens
acquir
total
number
alveolar
macrophag
dc
b
neutrophil
c
eosinophil
nk
cell
e
lung
analyz
flow
cytometri
result
present
cell
number
x
per
million
cell
data
shown
median
rang
three
technic
replic
per
cell
type
assay
p
p
p
p
propos
pip
use
prophylact
prevent
rsv
infect
highrisk
popul
like
elderli
possess
immun
system
perform
optim
due
immun
senesc
individu
could
treat
pip
formul
outbreak
rsv
possibl
respiratori
infect
partial
immun
protect
provid
pip
act
primarili
level
innat
immun
system
host
allow
us
specul
possibl
wellestablish
pip
therapi
protect
patient
multipl
viral
infect
would
benefici
one
protect
vulner
popul
major
diseas
like
influenza
coronaviru
rsv
infect
tend
transmit
rout
exposur
season
studi
confirm
pleiotrop
effect
yet
perform
fig
percent
weight
loss
surviv
extern
appear
clinic
score
balbc
mice
treat
pip
pb
day
panel
aec
day
panel
def
day
panel
gei
day
panel
jel
prior
intranas
pvm
challeng
mice
given
prophylact
intranas
treatment
pb
pip
time
point
indic
follow
pfu
pvm
challeng
anim
weigh
score
daili
treatment
day
follow
infect
data
weight
loss
repres
median
percentag
start
weight
error
bar
indic
interquartil
rang
percent
surviv
rate
express
median
percentag
total
number
anim
per
group
day
follow
infect
clinic
score
extern
appear
present
median
valu
group
entireti
anim
trial
experi
perform
twice
averag
n
total
number
anim
equal
per
group
